SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes

SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes

Using levels of neutralizing antibodies (nAbs), we evaluate the successful Chilean SARS-CoV-2 vaccine campaign, which combines different vaccine technologies and heterologous boosters. From a population-based study performed in November 2021, we randomly selected 120 seropositive individuals, organi...

Full description

Bibliographic Details
Main Authors: Aguilera, X. (Author), Apablaza, M. (Author), Castillo-Laborde, C. (Author), Cortes, L.J (Author), González, C. (Author), Hormazábal, J. (Author), Icaza, G. (Author), Nuñez-Franz, L. (Author), Pérez, C. (Author), Quezada-Gate, R. (Author), Ramírez-Riffo, C. (Author), Ramírez-Santana, M. (Author), Rubilar, P. (Author), Said, M. (Author), Vial, C. (Author), Vial, P. (Author)
Format: Article
Language:English
Published: MDPI 2022
Subjects:
AZD1222
BNT162b2
CoronaVac
COVID-19
cross-sectional design
neutralizing antibodies
SARS-CoV-2
vaccine-preventable diseases
vaccines
viruses
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items